Abbott Bets Hard on Cancer Diagnostics with New Deal

Its acquisition of Exact Sciences should catch the attention of all molecular testing laboratories

Abbott Laboratories’ deal to acquire Exact Sciences for $23 billion emphasizes the value that the in vitro diagnostics (IVD) manufacturer puts on cancer testing. Clinical laboratories involved with oncology should monitor the progress of this deal and whether other IVD companies pursue similar endeavors, said Larry Worden, principal at research and consulting firm IVD Logix. […]

To access this post, you must purchase The Dark Report.

Abbott Bets Hard on Cancer Diagnostics with New Deal

Its acquisition of Exact Sciences should catch the attention of all molecular testing laboratories

Comments

TABLE OF CONTENTS

Need A Group Membership? Company Discounts are Available!

You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

You have read 0 of 1 of your complimentary articles this month